ThRombosis ExclUsion STudy
Key facts
- Who runs it
- Diagnostica Stago
- Where
- Allentown, Bethlehem, Boston, Campbellsville, Chicago, Columbus, Dallas, Durham, Indianapolis, New Haven, Philadelphia, and St Louis, United StatesSee the 12 sitesAlso in 4 other countries, 8 sites
- Trial code
- Status
- Terminated
- People taking part
- 5,935 people enrolled
- Started
- 25 Jun 2018
- Ended
- 5 Sept 2024
- Type of study
- Observational, 2 groups
- Treatments tested
- DDimer test
- Record updated
- 25 February 2025
- Why it stopped
- Due to the unstability of samples included in the plasmabank using the reference method: VIDAS system, Stago decided to not use the plasmabank to assess the pre-specified primary objective. Therefore, this study was halted prematurely.
Who can take part
- Age
- Up to 79 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Patient is < 80 years old
- Patient presents at least one of these symptoms indicative of proximal DVT or PE:; symptoms for proximal DVT: leg pain, tenderness (discomfort through palpation), leg swelling, and /or edema,; symptoms for PE: hemoptysis, lung related chest pain, dyspnea
- Patient provides written informed consent to participate in the study
- Patient is willing to comply with specified follow-up evaluation at 3 months and can be contacted by telephone
Who cannot take part
- Patient presenting with a condition that may be associated with increased D-dimer levels, even in the absence of VTE, such as:; Fibrinolytic therapy within the previous seven (7) days,; Disseminated intravascular coagulation; Bone fracture or surgery (with general anesthesia longer than thirty (30) minutes) within the previous one (1) month,; Deep hematoma diagnosed by imaging techniques within the previous one (1) month,; Disseminated malignancies and active cancer (active cancer defined as: cancer for which therapeutic or palliative treatment is either ongoing at the time of enrolment or has stopped less than six (6) months before enrolment),; Sepsis, severe infections, pneumonia within the previous 1 month,; Known liver cirrhosis,; Pregnancy or having delivered within the previous 1 month,; Atherosclerotic vascular disease thrombosis within the previous 1month (e.g. myocardial infarction, stroke, coronary syndrome, peripheral artery disease stage III or IV),; Sickle cell disease,
- Patients with previous DVT/PE occurred less than three (3) months from screening
- Major co-morbid condition(s) or other reasons that could limit the patient's ability to participate in the study or to comply with follow-up requirements, or impact the scientific integrity of the study
- Ongoing therapeutic anticoagulants (curative and preventive regimen) started twenty four (24) hours or more before blood draw (except aspirin and platelet inhibitors)
- Previous anticoagulant therapy stopped less than three (3) months before blood draw (except aspirin and platelet inhibitors)
- Patients presenting with a suspect thrombotic event related to catheter implantation
- Suspect thrombotic events in other locations at screening, including distal to the knee and upper extremity DVT (based on standard of care examinations)
- Patients with known tissue plasminogen activator (tPA) deficiency
- Patient participating or who has participated within one month of enrolment in another investigational study
Where in United States
Also in 4 other countries, 8 sites
- Lehigh HospitalAllentown, United States
- St. Luke's University Health NetworkBethlehem, United States
- Massachusetts General HospitalBoston, United States
- Taylor Regional HospitalCampbellsville, United States
- Northwestern Medical CenterChicago, United States
- Ohio State UniversityColumbus, United States
- UT SouthwesternDallas, United States
- Duke Hemostasis and Thrombosis Research CenterDurham, United States
- Indiana University HealthIndianapolis, United States
- Yale New Haven HospitalNew Haven, United States
- Jefferson University HospitalPhiladelphia, United States
- Washington UniversitySt Louis, United States
About the trial
What the trial wants to find out
Primary objective: To demonstrate the ability of STA® - Liatest® D-Di XL combined with a clinical PreTest Probability (PTP) to safely exclude pulmonary embolism (PE) and deep venous thrombosis (DVT) as measured by Negative Predictive Value (NPV) and sensitivity.
Read full original descriptionShow less
Secondary objectives:
1. To estimate additional STA® - Liatest® D-Di XL accuracy parameters, including specificity and positive predictive value (PPV) 2. To constitute a plasma bank to be used for future studies with other DDi assays under development by Stago.
The 2 groups in the trial
- Pulmonary Embolism (PE)
Patients presenting with PE suspicion. Diagnosis will be performed according to Standard of Care. Plasma samples will be collected if PTP score is Low or Moderate. If diagnosis is negative, patients will be followed for 3 months to evaluate potential VTE development. Enrolment completed for this group : 13th February 2020
Treatment: DDimer test
- Deep Venous Thrombosis (DVT)
Patients presenting with DVT suspicion. Diagnosis will be performed according to Standard of Care. Plasma samples will be collected if PTP score is Low or Moderate. If diagnosis is negative, patients will be followed for 3 months to evaluate potential VTE development. Enrolment completed for this group : 29th March 2023
Treatment: DDimer test
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 25 February 2025